

8. Budget and financial issues:

- | | |
|---|--------------|
| 8.1. EMCDDA 2020 final accounts: opinion of the Management Board (<i>for adoption</i>) | EMCDDA/11/21 |
| 8.2. Information on procurements for non-administrative activities of a value greater than EUR 60 000 to implement the 2021 work programme (<i>for information</i>) | EMCDDA/12/21 |
| 8.3. EMCDDA's budget for 2022: Oral report on the state of play by the European Commission (<i>for information</i>) | |
| 8.4. Budgetary constraints for 2022 and perspectives to cope with shortage of resources (<i>for information</i>) | |

9. International cooperation:

- | | |
|---|--------------|
| - Candidate countries and potential candidate partners: | |
| 9.1. The EMCDDA/IPA7 project (Instrument for Pre-Accession Assistance) (<i>for information</i>) | EMCDDA/13/21 |
| - European Neighbourhood Partner Countries: | |
| 9.2. 'EU4 Monitoring Drugs' project (<i>for information</i>) | EMCDDA/14/21 |
| 9.3. Working Arrangement between the EMCDDA and Georgia (<i>for decision</i>) | EMCDDA/15/21 |
| 9.4. EMCDDA Technical cooperation project with Georgia (<i>for information</i>) | EMCDDA/16/21 |

10. Performance, planning and internal controls:

- | | |
|--|--------------|
| 10.1. EMCDDA Roadmap 2025 (<i>for adoption</i>) | EMCDDA/17/21 |
| 10.2. Reitox Development Framework Roadmap 2025 (<i>for discussion and endorsement</i>) | EMCDDA/18/21 |
| 10.3. State of implementation of the recommendations issued by the Internal Audit Service (IAS) (<i>for information</i>) | EMCDDA/19/21 |

11. Prevention and management of conflicts of interest:

- | | |
|---|--------------|
| 11.1. Periodic assessment of the implementation of the EMCDDA Policy for the prevention and management of conflicts of interest for Management Board members, substitutes and observers (<i>for decision</i>) | EMCDDA/20/21 |
|---|--------------|

12. Any other business

- | | |
|--|--------------|
| 12.1. Planning of meetings for 2022 (<i>for endorsement</i>) | EMCDDA/21/21 |
|--|--------------|